According to Reuters, citing three people briefed on the process, the US is working on rules for pharmaceutical companies investing in China that would likely preserve their ability to strike licensing deals for Chinese drugs – a notable departure from the Trump administration’s tightening of business with China for other industries under new national security legislation, and a looser framework than restrictions sought by some lawmakers.
Policy Snapshot
| Item | Detail |
|---|---|
| Drafting Agency | US Treasury Department |
| Subject | Rules governing US pharmaceutical investment in China |
| Expected Stance | Likely to allow investment in promising Chinese‑developed drugs and preserve licensing deal activity |
| Key Exclusion | Deals related to pathogens or biotechnology that could be weaponized |
| Status | Not finalized; subject to change – particularly if President Donald Trump weighs in |
| Timing | Unlikely to be unveiled ahead of next week’s Xi Jinping–Trump meeting in the US |
| Official Comment | Treasury and White House declined to comment |
Framework Details – What the Rules Would Allow
- Licensing Deal Preservation: The rules would likely allow US pharmaceutical companies to invest in promising new drugs being developed by Chinese companies, keeping in‑bound licensing transactions viable.
- National‑Security Carve‑Out: Investment would be permitted as long as assets are not related to pathogens or biotechnology that could be weaponized – drawing a bright line between commercial drug development and dual‑use biosecurity risk.
- Softer Than Legislative Asks: The framework would be looser than restrictions sought by some lawmakers, and marks a departure from tightening applied to other industries under new national security legislation.
- Fluid Process: Sources – who asked for anonymity as they are not authorized to discuss the process publicly – cautioned the rules have not been finalized and remain subject to change, particularly should President Trump intervene.
Market Impact & Outlook
- Deal Flow Unlocked: The rules could allow for billions of dollars of deals, helping fill US company drug pipelines while providing capital to Chinese biotech firms – a two‑way benefit for cross‑border pharma BD activity.
- China Licensing Thesis Intact: For US pharmas scouting China’s increasingly competitive oncology and immunology pipelines, preserving licensing capacity removes a major overhang that had clouded in‑licensing strategy.
- Geopolitical Timing: With Chinese President Xi Jinping due to meet Trump in the US next week, all four briefed sources consider it unlikely Treasury will unveil new pharmaceutical investment rules ahead of the meeting – leaving formal guidance on hold pending diplomatic dynamics.
- Execution Risk: Until finalized, the framework’s contours – including the scope of the pathogen/weaponizable‑biotech exclusion – remain subject to change, and presidential involvement could reshape the rules entirely.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding draft US Treasury rules, regulatory timelines, and expectations for cross‑border pharmaceutical investment and licensing activity. The rules are not finalized and are subject to change, including at the direction of the President. Reported details are based on anonymous sources briefed on the process as relayed by Reuters; actual policy outcomes, deal activity, and bilateral dynamics may differ materially.-Fineline Info & Tech
